@article {1642013,
	title = {Ocular complications with the use of radium-223: a case series},
	journal = {Radiat Oncol},
	volume = {17},
	number = {1},
	year = {2022},
	month = {2022 May 17},
	pages = {97},
	abstract = {BACKGROUND: Radium-223 is used for the treatment of osseous metastases in castrate-resistant prostate cancer, and has been shown to increase time to the first skeletal-related event, reduce the rate of hospitalization, and improve quality of life. It is well tolerated, with hematologic toxicity as the main adverse event. Thus far, no ocular complication has been reported in the literature after initial administration of radium-223 with a single case reported of ocular complications after a patient{\textquoteright}s second course of radium-223. CASE PRESENTATIONS: We present three cases of ocular complications after the use of radium-223 in patients with metastatic prostatic adenocarcinoma. Ocular complications presented as blurry vision, and formal diagnosis included uveitis and hyphema. CONCLUSIONS: Documentation of adverse events is exceedingly important due to the high incidence of metastatic prostate cancer and increasing interest for the use of radium-223 in other osteoblastic disease. The authors postulate that these ocular complications may be a result of radiation{\textquoteright}s potential effect on neovascularization, polypharmacy, or the biomolecular effects of radium-223 on integral signaling proteins, potentially coupled with poor underlying ocular health.},
	keywords = {Bone Neoplasms, Humans, Male, Prostatic Neoplasms, Castration-Resistant, Quality of Life, Radium},
	issn = {1748-717X},
	doi = {10.1186/s13014-022-02060-z},
	author = {Bloom, Julie R and Castillejos, Alexandra G and Jones, Brianna and Patel, Nimesh and Rosenstein, Barry S and Stock, Richard G}
}
